Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00

Oppenheimer reiterated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $63.00 from $102.00 previously

Guggenheim downgraded Keros Therapeutics from Buy to Neutral

H.C. Wainwright reiterated coverage of Keros Therapeutics with a rating of Buy and set a new price target of $47.00 from $100.00 previously

TD Cowen downgraded Keros Therapeutics from Buy to Hold

William Blair downgraded Keros Therapeutics from Outperform to Mkt Perform

BTIG Research downgraded Keros Therapeutics from Buy to Neutral

Jefferies initiated coverage of Keros Therapeutics with a rating of Buy

Cantor Fitzgerald initiated coverage of Keros Therapeutics with a rating of Overweight

Scotiabank initiated coverage of Keros Therapeutics with a rating of Sector Outperform

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review d

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patient

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeksDurable clinical responses were associated with improvements in patient-reported measures of fatigue in MDS patients early, and with continued improvement over timeData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffective hematopoiesis and address cytopenias, and also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scores LEXINGTON, Mass., Dec

− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis − Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau − Transaction builds upon Takeda's legacy in the treatment of hematologic cancers and advances company's global oncology strategy Takeda ((TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (NASDAQ:KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales LEXINGTON, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced an exclusive global development and commercialization license agreement wi

LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences: Piper Sandler 36th Annual Healthcare Conference Date and Time: Tuesday, December 3, 2024 at 10:30 a.m. Eastern timeLink: https://event.webcasts.com/starthere.jsp?ei=169970

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that three abstracts will be presented from its hematology program at the 66th American Society of Hematology ("ASH") Annual Meeting and Exposition to be held in person and virtually from December 7 through 10, 2024. Keros will be presenting additional results from its two ongoing Phase 2 clinical trials of elrite

LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the 2024 Cantor Global Healthcare Conference that will now begin at 8:00 a.m. Eastern time on Thursday, September 19, 2024. A live audio webcast of the fireside chat present

LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the Company has closed screening for the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"). As a result, Keros expects to complete enrollment by the end of September and present topl

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patient

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program," said Jasbir S. Seehra, Ph.D

Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigueData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scoresKeros will host a corporate update call and webcast today, June 17, 2024, at 8:00 a.m. ET LEXINGTON, Mass., June 17, 2024 (GLOBE NE

LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. Eastern time. "I am pleased to announce that Keros received positive feedback from the U.S. Food and Drug Administration regarding the KER-050 (elritercept) myelodysplastic syndromes ("MDS"

LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. "Keros remained focused on clinical execution and continued to make strong progress across our pipeline in the first quarter of 2024," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "We look

KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in patient-reported measures of fatigueBiomarker data demonstrate that KER-050 treatment has potential to reduce NT-proBNP a measure of cardiac stressPreliminary findings from ongoing Phase 2 clinical trial in myelofibrosis demonstrate that KER-050 can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit seen through reduction of spleen size and improved symptomsKeros will be hosting a conference call and webcast today, December 11, 2023, at 8

LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS) is re-issuing this press release solely to correct inadvertent typographical errors. The corrected press release reads in its entirety as follows: Keros Therapeutics announces U.S. Food and Drug Administration ("FDA") has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with background therapy in patients with pulmonary arterial hypertension LEXINGTON, Mass., July 24, 2023 – Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization o

Keros Therapeutics announces U.S. Food and Drug Administration ("FDA") has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with background therapy in patients with pulmonary arterial hypertension LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros will host a conference call and webcast to provide an overview of TROPOS,

Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to provide an update on its hematology franchise. LEXINGTON, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome

LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes ("MDS"), as well as initial data from its ongoing Phase 2 clinical trial of KER-050 in patients with myelofibrosis ("MF") and from its ongoing Phase 2 clinical trial of KER-047 in